Transmedics Group Inc (TMDX.O) has reached a significant milestone by hitting a 52-week high, reflecting strong investor confidence.
The stock's recent performance, with a price change of +4.69%, indicates positive market sentiment towards the company's growth prospects. This upward movement is notable amidst a broader market that is trading sideways with mixed signals.
Investors are closely monitoring the company's developments, as the healthcare sector continues to evolve. The achievement of a 52-week high could attract further attention from institutional investors looking for growth opportunities.
As the market remains uncertain, Transmedics Group's strong performance stands out, suggesting that technical factors are playing a crucial role in its stock movement.
Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 147.80 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
11 Analyst Rating
Wall Street analysts forecast TMDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for TMDX is 147.80 USD with a low forecast of 115.00 USD and a high forecast of 170.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
2 Hold
0 Sell
Strong Buy
Current: 140.990
Low
115.00
Averages
147.80
High
170.00
Current: 140.990
Low
115.00
Averages
147.80
High
170.00
TD Cowen
TD Cowen
Buy
maintain
$170
2026-01-21
Reason
TD Cowen
TD Cowen
Price Target
$170
AI Analysis
2026-01-21
maintain
Buy
Reason
TD Cowen says TransMedics shares are under pressure after Bridge to Life's VitaSmart received FDA clearance for liver transplantation. While VitaSmart is "technically competition" to TransMedics' OCS Liver, the system employs a back-to-base model using static cold storage, followed by hyperoxygenated perfusion in a bowl, the analyst tells investors in a research note. As a result, TD does not view VitaSmart as a threat to OCS Liver. Bridge to Life's system is "vastly different" from TransMedics' as it is not portable and does not allow surgeons to utilize biomarkers to assess organ function in the way that OCS Liver does, the firm contends. It continues to think TransMedics will maintain its dominance as new machine perfusion options come to market for liver. The firm views the selloff in shares today as unwarranted and reiterates a Buy rating on TransMedics with a $170 price target. The stock in afternoon trading is down 5% to $134.39.
Piper Sandler
Matt O'Brien
Overweight
maintain
$140
2026-01-02
Reason
Piper Sandler
Matt O'Brien
Price Target
$140
2026-01-02
maintain
Overweight
Reason
Piper Sandler analyst Matt O'Brien notes that every month, the firm tracks organ transplant volumes and the number of flights taken by TransMedics' medical jet fleet. Transplant volumes grew low single-digit in Q4 2025 versus Q3 2025. Liver, which the company is closely tied to, showed a strong 4.2% increase quarter-to-date. Piper keeps in mind that the Street is still expecting nearly 10% sequential growth in product sales in Q4 2025, which appears achievable to it based on machine perfusion share gains though room for upside seems limited. While the firm's model implies that service revenues may fall just short of expectations, it is within a reasonable margin of error for potential modest upside. Thus overall, Piper believes the Street's service revenue target is achievable, with modest downside risk and upside potential. The firm has an Overweight rating on the shares with a price target of $140.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for TMDX
Unlock Now
Canaccord
Buy
maintain
$147 -> $148
2025-12-17
Reason
Canaccord
Price Target
$147 -> $148
2025-12-17
maintain
Buy
Reason
Canaccord raised the firm's price target on TransMedics to $148 from $147 and keeps a Buy rating on the shares. The firm said they continue to be bullish on the Med-Tech sector heading into 2026. They point to strong underlying demand from an aging population, a focus on acute healthcare needs, the healthy pace of M&A, and a market that is receptive to IPOs as the foundation for our belief in our positive outlook in the upcoming year.
Needham
Buy
maintain
$148 -> $166
2025-12-08
Reason
Needham
Price Target
$148 -> $166
2025-12-08
maintain
Buy
Reason
Needham raised the firm's price target on TransMedics to $166 from $148 and keeps a Buy rating on the shares. The SRTR - Scientific Registry of Transplant Recipients - data for October 2025 indicates that the company's transplant volumes were likely above the average monthly rate in Q3, and based on the SRTR data, the firm estimates that TransMedics had a transplant volume of 460 in October vs. its estimated average monthly transplant volume of 394 in Q3, the analyst tells investors in a research note.
About TMDX
TransMedics Group, Inc. is a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure. The Company specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. It also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
